Zunzunegui Raul G, Chung Maureen A, Oruwari Jovita, Golding Daniel, Marchant Douglas J, Cady Blake
Departments of Surgery and Radiology, Breast Health Center/Women and Infants' Hospital, Brown University School of Medicine, Providence, RI, USA.
Arch Surg. 2003 May;138(5):537-40. doi: 10.1001/archsurg.138.5.537.
Women with breast cancer who have casting-type microcalcifications associated with multifocal invasion and extensive ductal carcinoma in situ (DCIS) form a subset of patients with a poor prognosis. Our study aims to identify the mammographic and pathologic features of this group.
Women with casting-type microcalcifications, multifocal invasion, and extensive DCIS were identified from our tumor board registry. Mammographic features, tumor characteristics, treatment, and survival rates were evaluated. Invasive tumors were limited to 14 mm or smaller.
University medical teaching hospital and breast cancer specialty clinic.
Of the 984 patients with breast cancer treated at our center, 15 patients were identified who had extensive casting-type calcifications and DCIS. Twelve of these patients also had multifocal invasive breast cancer. All had casting-type microcalcifications occupying more than 1 breast quadrant. All but 1 of the patients were treated using mastectomy with sentinel node biopsy or axillary node dissection. All but 1 patient had extensive grade 3 DCIS. Invasive tumors were negative for estrogen receptor and progesterone receptor expression in half of the patients, and 60% were positive for the HER-2-neu receptor. Positive axillary lymph nodes were found in 33% of patients, and 75% received adjuvant chemotherapy. After a median follow-up period of 20.5 months (range, 6-72 months), 1 patient had died and 1 had distant metastases. Of the 3 patients who had DCIS without invasion, 1 experienced a recurrence with infiltrating ductal carcinoma.
In women with small multifocal breast cancers with extensive casting calcifications and DCIS, the incidence of positive lymph nodes was 33%, with a tendency for poor tumor markers. These women appear to be at substantial risk for systemic disease; lymph node sampling and adjuvant systemic therapy are recommended.
患有与多灶性浸润及广泛导管原位癌(DCIS)相关的铸型微钙化的乳腺癌女性患者构成预后不良的一个患者亚组。我们的研究旨在确定该组患者的乳腺钼靶及病理特征。
从我们的肿瘤病例讨论登记处识别出患有铸型微钙化、多灶性浸润及广泛DCIS的女性患者。评估乳腺钼靶特征、肿瘤特点、治疗及生存率。浸润性肿瘤限于14毫米或更小。
大学医学教学医院及乳腺癌专科诊所。
在我们中心接受治疗的984例乳腺癌患者中,确定有15例患者有广泛的铸型钙化及DCIS。其中12例患者还患有多灶性浸润性乳腺癌。所有患者的铸型微钙化均占据超过一个乳腺象限。除1例患者外,所有患者均接受了乳房切除术加前哨淋巴结活检或腋窝淋巴结清扫术。除1例患者外,所有患者均有广泛的3级DCIS。一半的患者浸润性肿瘤雌激素受体和孕激素受体表达阴性,60%的患者HER-2-neu受体阳性。33%的患者腋窝淋巴结阳性,75%的患者接受辅助化疗。中位随访期20.5个月(范围6 - 72个月)后,1例患者死亡,1例有远处转移。在3例无浸润的DCIS患者中,1例出现浸润性导管癌复发。
在患有广泛铸型钙化及DCIS的小多灶性乳腺癌女性患者中,淋巴结阳性发生率为33%,肿瘤标志物有不良倾向。这些女性患者似乎有发生全身疾病的重大风险;建议进行淋巴结取样及辅助全身治疗。